Expert Insights on Emerging Data from the 2014 Global Congress on MS. Program Goals. Disclaimers. Current Clinical Data on New and Emerging MS Disease-Modifying Therapies. Glatiramer Acetate. Dimethyl Fumarate. Pegylated Interferon. Daclizumab HYP. Daclizumab HYP MRI Results. - PowerPoint PPT Presentation
Transcript of Expert Insights on Emerging Data from the 2014 Global Congress on MS
Expert Insights on Emerging Data from the 2014 Global Congress on
MS
Program Goals
Disclaimers
Current Clinical Data on New and Emerging
MS Disease-Modifying Therapies
Glatiramer Acetate
Dimethyl Fumarate
Pegylated Interferon
Daclizumab HYP
Daclizumab HYPMRI Results
You must view all 3 sections of this activity to earn CME credit.
Please click on the next section title to continue.
Biomarkers, Safety, and New Treatment Targets
MS Therapy Is Cost-effective
Biomarkers of Treatment ResponseAnalysis by Dhib-Jalbut
Biomarkers of Treatment ResponseAnalysis by Dhib-Jalbut (cont)
NatalizumabStopping Treatment
Natalizumab (cont) PML
Natalizumab (cont)Extended Dosing
PML Risk With Other DMTs
MS Management Algorithms
NEDA
You must view all 3 sections of this activity to earn CME credit.
Please click on the next section title to continue.